TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00318396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone preparation technique: compaction
Description: The bone is pressed very hard together before implantation of femoral component.
Study: NCT05028907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Study: NCT00318396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone preparation technique: conventional technique
Description: Bone is broached before implantation of femoral component.
Study: NCT03722576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium
Description: During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
Study: NCT02130440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol nasal spray
Study: NCT00062179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3-7 days before first dose of chemotherapy
Study: NCT03353844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Description: intradialytic exercise which start and finish in first hour of hemodiafiltration session
Study: NCT02864030

Intervention type: DRUG
Group type: OTHER
Intervention: ERIBULIN MESYLATE
Description: Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin.
Study: NCT03599609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg, once daily
Study: NCT03705832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger Extract
Description: 2gm Capsule of Ginger extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT00116142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Hormonal Suppression and Radiation
Description: Total Androgen Ablation and external beam radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Androgen Hormonal Suppression and Radiation
Description: Total Androgen Ablation and external beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression Therapy and Radiation Therapy
Description: Total Androgen Ablation and External Beam Radiation Therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Androgen Suppression Therapy and Radiation Therapy
Description: Total Androgen Ablation and External Beam Radiation Therapy
Study: NCT03582683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (CPSMP)
Description: Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self-Management Program (CPSMP)
Description: Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
Study: NCT04506736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARM
Description: The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spontanous ventilation
Description: volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
Study: NCT01720966

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection performed for metastatic disease from colorectal carcinoma

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection performed for metastatic disease from colorectal carcinoma
Study: NCT01694134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortancyl.
Description: Patients will receive an intradiscal injection of hydrocortancyl.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Study: NCT01384656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIK solution
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK solution
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Study: NCT01259245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi + PRP
Description: The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
Study: NCT02477124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal digital colposcope (TVDC)
Description: TVDC is a miniature colposcope used to obtain images of cervical tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care screening
Description: Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
Study: NCT00496015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612.
Description: 1 intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol.
Description: Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
Study: NCT01116401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide
Description: Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
Study: NCT01535807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CorMatrix extra cellular matrix (ECM)
Description: * Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.
Study: NCT03498807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventiltor P/V Loop
Description: determine the Optimal PEEP and keep 48hr on ARDS patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Impedance Tomography
Description: determine Optimal PEEP and keep 48hr on ARDS patients
Study: NCT02451917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
Study: NCT00228358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Laboratory-expanded T cells, given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Laboratory-expanded T cells, given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Intracellular cytokine staining (correlative study)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Intracellular cytokine staining (correlative study)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: ELIspot assay (correlative study)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: ELIspot assay (correlative study)
Study: NCT01316874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valrubicin, 800 mg
Description: Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
Study: NCT03833726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: LED group
Description: 5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control
Description: 5 Sessions of 8 minute with device off and heated gel, 7 days apart.
Study: NCT01768507

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 5 g (10 capsules) as single oral dose on day 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 5 g (10 capsules) as single oral dose on day 1
Study: NCT03708107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEP
Description: MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
Study: NCT03255135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
Study: NCT03071068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PlGF recombinant monoclonal antibody, 4mg dose
Description: 3 intravitreal injections of THR-317 4mg approximately 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PlGF recombinant monoclonal antibody, 8mg dose
Description: 3 intravitreal injections of THR-317 8mg approximately 1 month apart
Study: NCT04058041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization
Description: neural exercise Will be performed in the patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization
Description: neural exercise Will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and neural mobilization
Description: following the surgery patients will be treat with neural mobilization exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and neural mobilization
Description: following the surgery patients will be treat with neural mobilization exercises.
Study: NCT02599363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (LEE011)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03471247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Bed Cycle Ergometer
Description: Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine PT
Description: Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine PT
Description: Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
Study: NCT00003425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02041507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation method.
Description: Air insufflation colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Water Immersion during insertion, air insufflation during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Water Exchange during insertion, air insufflation during withdrawal.
Study: NCT03556163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified vertical internal mattress sutures + MWF surgery.
Description: Modified vertical internal mattress sutures were given after modified Widman flap surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple loop interrupted sutures + MWF surgery.
Description: Simple loop interrupted sutures were given after modified Widman flap surgery.
Study: NCT00934635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 9 mg tablet once a day followed by PET scan in approximately 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 6 mg tablet once a day followed by PET scan in approximately 2 hours

Intervention type: OTHER
Group type: OTHER
Intervention: PET Scan
Description: PET Scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 4 mg tablet once a day followed by PET scan in approximately 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 4 mg tablet once a day followed by PET scan in approximately 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once a day followed by PET scan in approximately 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once a day followed by PET scan in approximately 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 6 mg tablet once a day followed by PET scan in approximately 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 9 mg tablet once a day followed by PET scan in approximately 24 hours
Study: NCT04062110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaster cast
Description: Closed Reduction of Fracture and Application of Plaster Cast

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaster cast
Description: Closed Reduction of Fracture and Application of Plaster Cast
Study: NCT03540108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402
Description: The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
Study: NCT00471965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + 5-Fluorouracil/Leucovorin
Description: Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
Study: NCT02214472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02653820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Study: NCT00634504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucarpidase, high-dose methotrexate, leucovorin
Description: single intravenous dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose methotrexate, leucovorin
Description: standard of care, leucovorin every 6 hours
Study: NCT01534793

Intervention type: PROCEDURE
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Description: Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
Study: NCT03520530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Guard
Description: Patient will wear mouth guard while pushing in the second stage of labor